INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jan 09, 2004 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 51 | $15.35 | 64,596 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 60 | $480.34 | 520,299 |
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 74 | $16.99 | 66,642 |
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 74 | $17.02 | 66,517 |
| Apr 16, 2007 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 78 | $25.00 | 67,118 |
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 85 | $17.53 | 66,327 |
| Jan 09, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Open market or private sale of non-derivative or derivative security | 95 | $17.58 | 65,948 |
| Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $481.68 | 520,199 |
| Nov 02, 2015 |
Director, President Regeneron Laboratori
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $562.36 | 585,396 |
| May 01, 2012 |
Director, EVP CSO President Regeneron Re
|
Director, EVP CSO President Regeneron Re | Form 4 | Open market or private sale of non-derivative or derivative security | 100 | $133.95 | 866,106 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.